Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) issued its quarterly earnings results on Monday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04), FiscalAI reports.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $104.68 on Wednesday. The firm has a market capitalization of $6.31 billion, a P/E ratio of -51.57 and a beta of -0.34. Oruka Therapeutics has a 1-year low of $13.06 and a 1-year high of $107.55. The company’s fifty day moving average price is $84.58 and its 200-day moving average price is $61.25.

Insider Buying and Selling at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,290 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares in the company, valued at $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the sale, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 188,406 shares of company stock worth $12,019,683. 23.49% of the stock is currently owned by company insiders.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Viking Global Investors LP purchased a new position in Oruka Therapeutics in the third quarter valued at $51,280,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Oruka Therapeutics during the 4th quarter valued at about $51,840,000. Remedium Capital Partners LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $47,054,000. Deep Track Capital LP raised its holdings in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares during the period. Finally, State Street Corp raised its holdings in Oruka Therapeutics by 112.2% in the 4th quarter. State Street Corp now owns 1,383,847 shares of the company’s stock worth $41,944,000 after purchasing an additional 731,819 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Wedbush reissued an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Guggenheim restated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday. Finally, Barclays lifted their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.